- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05442632
Efficacy and Safety of Herombopag in Patients With Thrombocytopenia Before Hepatectomy
March 11, 2024 updated by: Lu Wang, MD, PhD, Fudan University
Director, Department of Liver Surgery, Fudan University Shanghai Cancer Center
This is a single center, randomized, controlled study, to evaluate the efficacy and safety of Herombopag in patients with Thrombocytopenia before hepatectomy.
Study Overview
Detailed Description
The purpose of this study is to assess the ability of Herombopag to elevate platelet counts thereby reducing the need for platelet transfusions in patients with thrombocytopenia before hepatectomy.
The clinical benefit of Herombopag will be measured by the proportion of subjects who avoid platelet transfusions, before, during and up to 7 days after undergoing an hepatectomy.
In addition, bleeding events will be monitored during this time.
The number of transfusions, safety events will be monitored during this time and for up to 3 months after undergoing a hepatectomy to help further evaluate clinical benefit.
Study Type
Interventional
Enrollment (Estimated)
96
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Lu Wang, Professor
- Phone Number: 18121299555
- Email: wang.lu99@hotmail.com
Study Contact Backup
- Name: Ti Zhang, Professor
- Phone Number: 15800680751
- Email: zhangti@shca.org.cn
Study Locations
-
-
-
Shanghai, China, 200062
- Recruiting
- Fudan University Shanghai Cancer Center
-
Contact:
- Lu Wang, M.D.
- Phone Number: +86-15800680751
- Email: w.lr@hotmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- 1. Male and female subjects ≥18 years of age;
- 2.Patients prepared to receive hepatectomy;
- 3.50×10^9/L≤platelet count≤80×10^9/L;
- 4.Child-PUgh score A or grade B (≤7 );
- 5.Life expectancy ≥3 months;
- 6.Normal Bone marrow hematopoiesis and renal function;
- 7.Voluntary participation and written informed consent;
Exclusion Criteria:
- 1.Central nervous system diseases caused by liver disease;
- 2.Platelet transfusion within 7 days prior to the first dose of study drug;
- 3.History of any primary hematologic disorder;
- 4.History of arterial or venous thrombosis, including thrombosis of any part of the splenic-mesenteric system;
- 5.Pre-diagnosed Immune Thrombocytopenic Purpura (ITP);
- 6.History of Myelodysplastic Syndrome (MDS);
- 7.Those with bleeding tendency,have evidence of hereditary bleeding or blood coagulation disorder;
- 8.Females who are pregnant (positive β-hCG test ) or breastfeeding;
- 9.Subjects who have participated in another investigational trial within 30 days prior to Visit 1;
- 10.Those with uncontrollable neurological and psychiatric diseases or mental disorders, poor compliance, unable to cooperate and describe treatment response;
- 11.Subjects with known intolerance or allergy to any of the ingredients in eltrombopag tablets;
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental: 1
durg:Hetrombopag 5mg,once daily,oral
|
The patients received Hetrombopag 5mg orally d1-14 days, surgery will be conducted at d6-14 day
|
Experimental: Experimental: 2
Ndurg: Placebo 5mg,once daily,oral
|
The patients received Placebo 5mg orally d1-14 days, surgery will be conducted at d6-14 day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The proportion of patients who require blood product infusion or intervention with platelet raising drugs due to bleeding during the perioperative period
Time Frame: From the start of using the investigational drug to 7 days after surgery completion
|
Platelet transfusions were administered at the discretion of the investigator and the physician performing the hepatectomy.
|
From the start of using the investigational drug to 7 days after surgery completion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients with bleeding after surgery need intervention.
Time Frame: up to 7 days following surgery。
|
The World Health Organization Bleeding Scale was used to assess bleeding following surgery..
The range of possible scores is 0 to 4. Grade 0 is no bleeding; Grade 1 is petechiae (small [1-2 millimeter] red or purple spot on the body, caused by a minor hemorrhage); Grade 2 is mild blood loss; Grade 3 is gross blood loss (requiring a transfusion; and Grade 4 is debilitating blood loss (retinal or cerebral associated with fatality).
|
up to 7 days following surgery。
|
Incidence of deep venous thrombosis
Time Frame: up to 3 months following surgery.
|
Imaging examination will be conducted at d1、d3、d5、d7、d14、end of one month、 end of three month after surgery, to evaluate deep venous thrombosis if necessary.
|
up to 3 months following surgery.
|
Incidence of liver failure
Time Frame: up to 3 months following surgery.
|
Posthepatectomy liver failure is defined as: A postoperatively acquired deterioration in the ability of the liver to maintain its synthetic, excretory, and detoxifying functions, characterized by an increased international normalized ratio A postoperatively acquired deterioration in the ability of the liver to maintain its synthetic, excretory, and detoxifying functions, characterized by an increased international normalized ratio and hyperbilirubinemia on or after postoperative day 5.
If international normalized ratio or serum bilirubin concentration is increased preoperatively, Post hepatectomy liver failure is defined by an increasing international normalized ratio and increasing serum bilirubin concentration on or after postoperative day 5 Other obvious causes for the observed biochemical and clinical alterations such as biliary obstruction should be ruled out.
The evaluate of liver failure was conducted at d1、d3、d5、d7、d14、end of one month、 end of three month after surgery.
|
up to 3 months following surgery.
|
Changes in preoperative Platelet count compared to baseline
Time Frame: baseline and up to 1 days prior to surgery
|
Platelet count were determined from blood draws.
platelet count collect on baseline and prior to 1 days of surgery.
Missing platelet count assessments at any given time point was considered to be a non-response at that point and were not estimated
|
baseline and up to 1 days prior to surgery
|
Proportion of patients whose Platelet count returned to ≥80×10^9/L
Time Frame: baseline and up to 1 days prior to surgery
|
Platelet count were determined from blood draws.
platelet count collect on baseline and prior to 1 days of surgery.
Missing platelet count assessments at any given time point was considered to be a non-response at that point and were not estimated.
|
baseline and up to 1 days prior to surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Lu Wang, Professor, Fudan University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 25, 2022
Primary Completion (Estimated)
December 1, 2025
Study Completion (Estimated)
December 30, 2025
Study Registration Dates
First Submitted
June 27, 2022
First Submitted That Met QC Criteria
June 30, 2022
First Posted (Actual)
July 5, 2022
Study Record Updates
Last Update Posted (Actual)
March 13, 2024
Last Update Submitted That Met QC Criteria
March 11, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- OBU-SH-HCC-II-010
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatopathy
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Medical University of LodzCompleted
-
Institut PasteurCompletedFibrosis | HepatopathyFrance
-
West China HospitalRecruiting
-
Consorci Sanitari de l'Alt Penedès i GarrafRecruitingLiver Diseases | Type 1 Diabetes | Non-alcoholic Fatty Liver Disease | Glycogen HepatopathySpain
Clinical Trials on Hetrombopag
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingChemotherapy-Induced Thrombocytopenia
-
Tongji HospitalNot yet recruitingMyelodysplastic Syndromes
-
Sun Yat-sen UniversityNot yet recruitingChemotherapy-Induced Thrombocytopenia
-
Institute of Hematology & Blood Diseases HospitalRecruitingAllogeneic Hematopoietic Stem Cell Transplantation | Hematological DiseaseChina
-
Jiangsu HengRui Medicine Co., Ltd.UnknownPurpura, Thrombocytopenic, IdiopathicChina
-
Wuhan Union Hospital, ChinaJiangsu Hengrui Pharmaceutical Co., Ltd.Not yet recruitingAplastic Anemia | Primary Immune ThrombocytopeniaChina
-
Peking Union Medical College HospitalNot yet recruitingDrug Effect | Aplastic AnemiaChina
-
Jiangsu HengRui Medicine Co., Ltd.CompletedBioavailability StudyChina
-
Jiangsu HengRui Medicine Co., Ltd.CompletedIdiopathic Thrombocytopenic PurpuraChina
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNot yet recruitingChemotherapy-induced Thrombocytopenia